Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial

IMPORTANCE: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone. OBJECTIVE: To determine the efficac...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JAMA
Main Authors: Tap, William D., Wagner, Andrew J., Schöffski, Patrick, Martin-Broto, Javier, Krarup-Hansen, Anders, Ganjoo, Kristen N., Yen, Chueh-Chuan, Abdul Razak, Albiruni R., Spira, Alexander, Kawai, Akira, Le Cesne, Axel, Van Tine, Brian A., Naito, Yoichi, Park, Se Hoon, Fedenko, Alexander, Pápai, Zsuzsanna, Soldatenkova, Victoria, Shahir, Ashwin, Mo, Gary, Wright, Jennifer, Jones, Robin L.
Format: Artigo
Sprog:Inglês
Udgivet: American Medical Association 2020
Fag:
Original Investigation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7139275/
https://ncbi.nlm.nih.gov/pubmed/32259228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.1707
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker